Hand and Wrist: Bumps Part 2
Charles Goldfarb (You): Oh, hey, Chris.
Chris: Hey, Chuck. How are you?
Charles Goldfarb (You): I'm great. I'm great. What could be better?
Charles Goldfarb (You): Recording on a Saturday morning with you.
Chris: That's right. I'm about to head in and do a resident research curriculum lecture. Super excited about that and, uh, continuing commitment to the betterment of our resident research program.
Charles Goldfarb (You): Is this to the entire residency, or is it just to one or two classes?
Chris: To one class. So they have a structured curriculum that our partner, uh, David Bergen, has put together. And so I'm lecturing to the PGY IIs this morning about writing a specific AIMS page, which maybe some of them have done that in the past, some of them may never have seen that before.
Chris: So— so I usually give a lecture but then make them use the time to get started on their AIMS page, uh, because I think it's important for them to actually use the study hall time that they've been allocated. They're all required to be there in person, uh, so, you know, might as well make use of the time.
Charles Goldfarb (You): Yeah. Yeah, yeah. Um, well, let's— we can catch up on a couple things.
Charles Goldfarb (You): But I think, uh, just to highlight the episode, you know, this is part two of Han: Lumps and Bumps, and Chris and I want to hit, uh, not really the esoteric, but more of the common things we see, um, and just talk through them. Um, things like enchondromas, giant cell tumor of tendon sheath, which I don't even think is called giant cell tumor of tendon sheath anymore.
Charles Goldfarb (You): Um, things like that.
Chris: Yeah, so I think it's the stuff that we see, but also the stuff that we worry about that we should not miss. Uh, I think that's probably how I frame this kind of thing. And this is a follow-up on our part one, in which we already reviewed things like volar and dorsal ganglions, retinacular cysts, and mucous cysts.
Chris: So, uh, before we jump in, why don't we acknowledge, uh, one of our sponsors?
Charles Goldfarb (You): Absolutely. The Upper Hand is sponsored by practice link.com, the most widely used physician job search and career advancement resource.
Chris: Becoming a physician is hard. Finding the right job doesn't have to be. Join PracticeLink for free today at www.practice link.com/theupperhand.
Chris: Speaking of The Upper Hand, it was recently recognized as the number 3 orthopedic podcast, uh, which we got an email about, which was super cool and interesting. I immediately forwarded this to my parents, uh, to make sure they were fully aware of how famous, uh, their son is as the, uh, the lesser half of The Upper Hand.
Charles Goldfarb (You): I— you know, it's funny. Uh, I— I— because I got the email. We get— I don't know about you, but in my— in my various emails, I get so many things like this.
Charles Goldfarb (You): And— or not like this, but so many things to the podcast, and I don't know kind of, um, you know, I don't know what to make of them. I really read through them, uh, sometimes.
Charles Goldfarb (You): Sometimes I don't read through them. Anyways, I, you know, I read through this one.
Charles Goldfarb (You): I'm like, oh, you know, maybe we're number 30 out of 60 or whatever. But we were.
Charles Goldfarb (You): We were number 3. And, uh, it— you know, that is another reason for us to be grateful to you, the listener.
Charles Goldfarb (You): And, uh, it's another reason we keep doing this, because it seems like, uh, we're doing something right.
Chris: Absolutely. So keep sending us, uh, suggestions for topics. Uh, leave that 5-star review.
Chris: Um, you know, it— it is interesting, the different touchpoints that the podcast has. Um, you know, and so some people know us only from this.
Chris: Other people know us by the many papers and presentations that, uh, that you write and you give. But, uh, we'll take it.
Chris: It's fun. And we're excited.
Chris: We've got a live episode coming up, uh, in the— in Edinburgh. Did I say that?
Chris: Edin?
Charles Goldfarb (You): I— I still don't know how to freaking say it. I've been told 10 times how to say it, and then my wife said Edinburgh last night, and I'm like, I know it's not that.
Chris: It's like— so anyway, we have a live episode coming up at a British Society meeting in Scotland. Let me put it that way. Um, so we encourage everybody to come out, uh, bring your energy, bring your questions.
Chris: Uh, we'll have some structure to that, we promise. Uh, and, uh, you know, keep, uh, keep your listener questions coming, uh, and topic suggestions.
Charles Goldfarb (You): Yeah, and we'll figure out how to pronounce our— the— the home of our host.
Chris: So I— I think I told you this. We were— I was— we were on vacation somewhere on holidays, they say over there. And, uh, I was telling somebody I just met, and I was like, oh, we're going to Toronto.
Chris: And she's like, no, I'm from there. We know you're a tourist if you say Toronto.
Chris: It's Toronto. Like, the— the second T isn't pronounced.
Chris: I was like, oh, that makes a— thank you for telling me that. I would never have picked up on that.
Charles Goldfarb (You): No, not at all. Uh, that's awesome. Um, yeah, well, I'm excited to— to visit Scotland.
Charles Goldfarb (You): I've never been there. I'm not really a golfer, so that's why a lot of, at least, people in— you know, in the United States may travel to Scotland.
Charles Goldfarb (You): But I hear it's a beautiful place, and even in November, uh, it should be spectacular, although maybe a little chilly, maybe a little rainy. But it's okay.
Chris: I think it'll be fun. And, uh, I think your schedule's a little more loaded than mine, so I'm excited to do a little exploring. I think I have one— one day that's very, very light, so I'm excited about that.
Chris: I'm going to try not to hole myself up and do work. I'll try to actually get out and— and see you in town.
Charles Goldfarb (You): Yeah, for sure. For sure. All right, let's jump in.
Charles Goldfarb (You): Um, and enchondromas are a part of every hand surgeon's life. I may see more than most, because in kids, um, and this is going to test some of our listeners, you know, multiple enchondrosis— enchondromas, um, occur in Alier's disease and Maffucci syndrome.
Charles Goldfarb (You): But for me, it's Alier's disease, where, uh, one half of the body is extraordinarily affected. So it's only right or left.
Charles Goldfarb (You): Uh, it can be upper more than lower, or vice versa, but, uh, it's really an interesting thing. But that's not what most of us see on a daily basis.
Charles Goldfarb (You): What— what's your common scenario?
Chris: Yeah, so this doesn't come up for me, but, you know, when it comes up, it's like, oh, yeah, I remember that. Um, so I'm not seeing the— the, you know, the Alier's and Maffucci's kids that you're seeing, but it's usually a pathologic fracture. You know, so incidentally found that, you know, there's a proximal phalanx fracture, and then, oh, there's a lesion.
Chris: Um, noticed. So maybe this is something that had been, you know, slowly but surely, the bone— uh, the cortex had been wearing away over time, and then maybe a— a lower level of, uh, energy injury, um, resulted in a fracture.
Chris: Or sometimes it just shows up like a normal fracture and you find it on the X-ray. Um, how do you typically— so outside of the syndromic population, uh, say you see a— a proximal phalanx or middle phalanx fracture, and incidentally, um, you've noted that there's, um, uh, a lesion in the bone.
Chris: How are you approaching that, uh, process, not only from how you think about treatment options, but also how you counsel patients?
Charles Goldfarb (You): Yeah, so I— I would say the way I was taught is not the way I practice today. And I'm curious as to your approach, but what I was taught— so these lesions, um, uh, are often expansile, um, and that's what leads to the weakening of the cortical bone. They have a pretty classic, glassy appearance.
Charles Goldfarb (You): And when you— when you're in the OR, you know immediately if you have an enchondroma. Um, but what I was taught is, let the fracture heal, and then come back and curettage plus-minus bone graft.
Charles Goldfarb (You): And I don't think in 2026 patients want that. They just want one intervention, and they don't want to be immobilized twice and all of that.
Charles Goldfarb (You): And so when I see these, like a pathological fracture, which I do think is the scenario, um, talk to the patient about what we expect. Go to the OR, curettage.
Charles Goldfarb (You): If there's a fracture, I generally add some disruptive bone graft. You can use off-the-shelf.
Charles Goldfarb (You): And some say you don't have to use anything, but I add— I add something, usually, uh, distal radius. And I pin it, if need be, uh, for the fracture, especially if it's, you know, even mildly displaced.
Charles Goldfarb (You): And— and I think it's a kind of a one-stop treatment, and patients do well with it. What's your approach?
Chris: Yeah, pretty similar. I mean, I know the— you know, the teaching is as you described, at least the class of teaching is as you described. Um, but in the— in the context of actually having a fracture, um, you know, most people are like, hey, just get it done.
Chris: Like, you know, go in there, curettage it out, and fix— fix the fracture. Uh, you know, graft everything, fix the fracture, and be done.
Chris: Um, it's kind of uncommon to try to stage those things out nowadays. Um, so I— I think it's important to recognize, important to tell, you know, the patient, hey, you're still at risk, you know, your bone is going to be weaker, etc.
Chris: You know, I think if it truly is an enchondroma, it is benign, so it's important to counsel them about that, to make sure it's not anything, uh, more sinister or nefarious. Um, you know, and I guess the question I wanted to ask you now is, you know, say you've found it incidentally, um, you know, and maybe they have pain but haven't fractured.
Chris: Um, you know, is this something where— how do you talk to them about curettage and grafting in that context?
Charles Goldfarb (You): Yeah, I mean, if it's enlarging the cortices, then I tell them, at least in my mind, it makes sense at their convenience, um, electively, to deal with this. And, um, because ultimately they're going to deal with it non-electively, and, you know, that's just less desirable. Um, but my approach is the same.
Charles Goldfarb (You): You know, for— for technically, this is a dorsal— for me, it's always a dorsal approach. And I either split the tendon in over a very small segment.
Charles Goldfarb (You): You know, you don't need a massive tendon split. Uh, or if you can work around the tendon, great.
Charles Goldfarb (You): Small curette to— to break through the very paper-thin cortex is typically the scenario. Uh, aggressive curettage, I mean, get every little bit of this out, irrigate like crazy.
Charles Goldfarb (You): Um, I mean, like I said, I— I believe in bone grafting these.
Chris: Um, so you— you typically will use distal radius autograft, you said? So cancellous autograft?
Charles Goldfarb (You): Yeah. I do it for two reasons. One, uh, or three reasons, I guess.
Charles Goldfarb (You): One, I think it's the best option, uh, better than off-the-shelf. Two, cost-wise, um, it's obviously a big difference.
Charles Goldfarb (You): Uh, I don't think it inconveniences the patient terribly. And I believe in its, uh, you know, the— the benefits from a bone healing and, uh, get-back-to-life, uh, pace as well.
Charles Goldfarb (You): Meaning it's faster.
Chris: Um, no prophylactic pins?
Charles Goldfarb (You): No. No. I mean, obviously, I guess anything's possible.
Charles Goldfarb (You): But with this type of, uh, you know, a single lesion, they're not usually massive. When you get into the Alier's disease, where you're multiple, you know, phalanx involvement, distal radius involvement, it's a different scenario altogether.
Chris: So just to shift gears a bit, so what if, um, you're seeing a patient, uh, and they've got a mass along the volar aspect of their finger, kind of, you know, closer to the PIP crease, um, along kind of the radial or ulnar side. It's, you know, maybe the size of a pea. Um, you know, not any bigger than that.
Chris: Um, and they're just like, they want to know what it is. And maybe they want it out.
Chris: Um, how do you approach that evaluation?
Charles Goldfarb (You): Yeah, um, the, you know, location matters for these.
Charles Goldfarb (You): And we can talk about a couple of these. I— I— when I think about, um, and I don't know what you have in mind, but, you know, the— the soft tissue masses that are firm, they're not rapidly growing.
Charles Goldfarb (You): They may be growing, but they're not rapidly growing. There's no— you know, I always try to check for— this is funny.
Charles Goldfarb (You): I always check for— for any type of, um, you know, nodes or glands or— or any type of swelling along the extremity. And I never find it, ever.
Charles Goldfarb (You): Ever. But I always check.
Charles Goldfarb (You): And maybe one day I'll— I'll— I'll feel something, like a swollen lymph node. But anyways, I always check that.
Charles Goldfarb (You): But if there's none of that, then, you know, I have a soft tissue, um, you know, things I think about. I think about epidermal inclusions list.
Charles Goldfarb (You): I think about giant cell tumor of tendon sheath. Uh, I potentially think about a nerve tumor, uh, which I'd love your thoughts on.
Charles Goldfarb (You): And ultimately, you know, the patient and I together decide, A, do we want to do advanced imaging, uh, which could be, for me, ultrasound or MRI. I just don't love MRI in the fingers or, you know, I just don't.
Charles Goldfarb (You): So it's usually ultrasound if we want to confirm soft tissue versus, uh, uh, cyst. Um, or it's a, um, you know, it's a excision, an excisional biopsy, so to speak, where you remove the entire lesion and send to path.
Charles Goldfarb (You): But is that how you think about it? Do you think about it differently?
Chris: No, I think about it the same way. I mean, um, you know, so I— when I evaluate, uh, I look if there are any overlying skin changes. Maybe this is a weird formation, like a skin cancer, that kind of thing.
Chris: Usually not the case. Um, you know, I'll do a Tinel sign just to make sure.
Chris: I'll check two-point discrimination, because along the lines you're thinking, is this a nerve sheath tumor, etc. Um, you know, is, you know, is it, um, does it appear to have, like, you know, vessels along it, or is it vascular in nature?
Chris: Um, which oftentimes is not. Um, is it along the tendon?
Chris: Is it, like, running adjacent to the tendon? Does it move with the— with the finger?
Chris: Is it padded to the skin? Um, is it close to a joint?
Chris: Is it like a weird variant of a mucous cyst, in terms of I've seen them coming off the PIP. I've also seen cysts associated with the extensor tendon sheath that, you know, look like they could be coming off the joint, but they're not.
Chris: And then ultimately, I probably will get some form of, uh, radiograph, whether that's a fluorescein image or a formal X-ray. And then if it's just looking a little weird, that's my threshold to get other imaging, whether that is ultrasound or MRI.
Chris: But ultimately, having a conversation with the patient, you know, usually if they're coming in asking what it is, many of them want it out, um, and telling them, hey, if you really want it out, you're trading a bump for a scar. A scar can be painful too, etc.
Chris: Um, and then doing an excisional biopsy, which, you know, I think that in— in the classic orthopedic training, you know, um, there's usually not a role for an excisional biopsy outside of hand. Um, but, you know, hand, I think, is a little bit different with how we manage things, because, like we mentioned in the last episode, the incidence of malignancy in the hand is really, really low.
Chris: Not zero, but really low.
Charles Goldfarb (You): Not zero and— not zero, and certainly, you know, we think about that concern a lot. You know, I have— I've been doing this a long time, and every couple of years, uh, I encounter one, and hopefully I don't miss any. Any.
Charles Goldfarb (You): You know, like the threshold, you know, hopefully you're just not missing any. But, you know, sometimes these— these things are obscure.
Charles Goldfarb (You): So, uh, I like how you described it. Uh, surgically, you know, thankfully, most of these are pretty straightforward.
Charles Goldfarb (You): So an epidermoid inclusion cyst, uh, for those who are not familiar, um, it's usually either a trauma, where the epidermal layer or some cells from the epidermal layer are pushed, uh, subcutaneously, or it can be a blocked hair follicle. Um, they're absolutely classic.
Charles Goldfarb (You): You know, it's the, you know, when you cut the skin and get into this cyst, it— you know immediately what it is. And I don't even send that to pathology.
Chris: I still will send it. Um, you know, the other context I've seen it's in is like a splinter or, you know, some kind of a thorn or foreign body that they may or may not remember having. Um, but I will still send it, typically, um, just because I think it makes a lot of people at ease.
Chris: And in— in some cases, patients are awake, and I ask them, do you want me to send this or not? So we can say we had a conversation about it.
Chris: Um, but yeah, that one's pretty straightforward. And I mean, that can, you know, the epidermal inclusion cyst can, I've seen them both on the glabrous and non-glabrous portions of the hand and fingers.
Chris: Um, so that's just something to keep in mind. Um, you know, you mentioned earlier about every now and then you get a, um, you know, an occurrence of a malignancy.
Chris: And I had an interesting patient, uh, interesting case that was sent to me by a dermatology group, um, that is close by to the outpatient center where I practice. And it ended up being a varicose carcinoma, which is pretty uncommon.
Chris: Um, but immediately, it was good to have that relationship with the dermatologist who sent it, because I sent them right back and said, hey, we excised this, here's the, you know, I actually got margins just because I wanted to— something was weird about it, where I sent margins instead of just a mass, and I'm glad I did.
Charles Goldfarb (You): Wow. Yeah. That's, uh, that's interesting.
Charles Goldfarb (You): Yeah, I think, you know, if— if what the— we talk about AI a lot, and AI is wonderful, um, in many, many ways. But what experience and pattern recognition and lesion recognition is just so important here.
Charles Goldfarb (You): And so there are many times where I am 100% confident in what I see. Um, but if I'm not, which is what you described, then you act differently, because you know that something is off.
Charles Goldfarb (You): And, uh, that's great. I mean, that— that's what— that's what an experienced hand surgeon brings to you.
Charles Goldfarb (You): And we all gain experience over time. And— and that's why, you know, we've preached over and over that we should not be afraid to ask for help.
Charles Goldfarb (You): And I still do. I still do.
Charles Goldfarb (You): I, uh, have a couple things right now where I just keep logs of what, uh, you know, not— not tumors or not masses, but I just— there's always questions where I don't know the answer. And I— I leverage my partners.
Chris: So one other, um, mass that comes up is, uh, a giant cell tumor of tendon sheath. Um, how has that kind of shown up in your practice? I've seen a couple of cases of this.
Chris: Uh, and, you know, one that, uh, I guess the teaching that I had was that this is not a malignancy, but it is an aggressive, uh, benign mass with a penchant for recurrence.
Charles Goldfarb (You): Yeah, well said. Uh, again, very characteristic. Um, a yellowish, uh, appearance once you've, uh, uh, gone after it.
Charles Goldfarb (You): Um, can emanate from the tendon sheath, can emanate from the joint. And it also sometimes it does— it's not clear where it's coming from.
Charles Goldfarb (You): Those are the ones you want, uh, where you can isolate it, take it out, and you can tell the patient, yes, there's theoretically a risk of recurrence, but it's low. When they're more diffuse, uh, when they're more, uh, clearly coming from deep, those are the ones I worry about.
Charles Goldfarb (You): And the recurrence rate, uh, theoretically, is up to 30% for those joint-based, uh, clearly joint-based, uh, giant cell tumor of tendon sheaths. Um, it's a great surgery to— to do with a resident or a fellow.
Charles Goldfarb (You): Uh, it— it— they're just enjoyable. I— I probably see two of these a year, so it feels pretty common for me.
Chris: Yeah, I don't see them that often. I think it comes up once every couple of years. Um, you know, and this is one where I will get imaging, uh, typically ahead of time, so that, for me, that'd be an MRI with and without IV contrast.
Chris: Um, you know, uh, just to get a better appreciation of it. Um, you know, knock on wood, for me, these have not recurred.
Chris: But, you know, it is an important conversation to have with the patient, uh, saying it's possible, uh, especially with the ones you're describing that are coming off of the joint. Um, what other— what other lumps and bumps have you seen that, you know, um, a budding hand surgeon should be aware of?
Charles Goldfarb (You): Uh, yes. Um, well, let's— let's talk about your favorite topic before I share a, um, a case. Um, nerve tumors.
Charles Goldfarb (You): So, you know, you mentioned, you know, sometimes it's pretty obvious if it's a nerve tumor. Sometimes it's not.
Charles Goldfarb (You): You mentioned a Tinel's as part of your examination, uh, two-point discrimination. Um, what— how do you think about, uh, both benign and maybe not so benign, uh, hand, uh, nerve tumors?
Chris: You know, they— they actually don't come up for me as often as I would think they would. Um, you know, and I think it kind of depends on the nerve. Like, you know, I have seen them on digital nerves, but it's somewhat uncommon.
Chris: Um, I'm typically seeing these in larger nerves. Um, you know, so I've seen one recently in, um, coming off of the medial brachial cutaneous nerve, up by the plexus.
Chris: Uh, comes up for sciatic nerves. Um, you know, so those are— and peroneal nerves.
Chris: Those are the contexts in which I'm seeing them. Um, you know, I think that the textbook teaching is that if it's truly a benign, uh, nerve sheath tumor and not a malignant nerve sheath tumor, it should shell out relatively easily in terms of excision.
Chris: It typically does not, um, entangle itself too much into the fasicles of the nerve. Um, although I have seen ones that have been benign, but not easy to shell out.
Chris: And that's when you get a little, no pun intended, nervous. Uh, because typically, you know, the patient is neurologically intact.
Chris: And if it's a mixed nerve, now you're dealing with potentially creating a motor deficit, uh, if you're having a hard time, uh, disentangling the mass. I— I still will send these for pathology, even if everything looks, you know, it— it's very buttoned up in terms of it shells out easily, just because I don't want to miss something there.
Chris: Um, you know, but I think it's all— it's all about the counseling. I tell people, textbook-wise, it's supposed to come out easily, but there is a chance that you're going to have some kind of neurologic deficit, and I would be the one to reconstruct it anyway.
Chris: Um, what's been your experience, uh, with these cases?
Charles Goldfarb (You): Yeah, uncommon for me as well. Um, I do, you know, especially on the larger nerve, so in the forearm for me, I wouldn't go more proximal than that. Uh, I will image these.
Charles Goldfarb (You): Uh, I— I rarely include contrast dye. You mentioned it for evaluating giant cell tumor of tendon sheath.
Charles Goldfarb (You): I— I just don't do it unless I'm really concerned about malignancy. Um, and yeah, I— I— if it's a situation where I'm unable to, you know, isolate the growth or shell it out, as you say, then I— I— I take a biopsy rather than being overly aggressive on that first occasion.
Charles Goldfarb (You): Now, again, it hasn't really happened commonly for me, but I can think of one case years ago, I— I— where I'd rather not, um, you know, be overly aggressive. So if you're concerned that you might have to do more than just take out this lump, how do you counsel the patient preoperatively?
Charles Goldfarb (You): I guess that's where it gets tricky.
Chris: That's all that's going to be, you know, staged. You know, so if it's a little more concerning, like you said, I'll take out as much as I can and then see what, you know, because oftentimes you will have recovery of whatever deficit is. Uh, if you have a deficit that, um, a lot of times it will recover.
Chris: And if not, uh, if the— if the biopsy comes back as something suspicious, uh, for malignancy, then you're going in a different direction. Um, but if it comes back as benign and then you have a neurologic deficit, if it recovers, great.
Chris: If not, you can either reconstruct that segment, uh, with a graft of some sort, or you can do a distal— distally-based strategy, depending on the context, whether that's a nerve transfer, etc. So.
Charles Goldfarb (You): Yeah.
Chris: So speaking of nerves.
Charles Goldfarb (You): Totally.
Chris: This episode is brought to you by Check Point Surgical, a provider of innovative solutions for peripheral nerve surgery. A lot has been happening at Check Point lately, from new products and technologies to a growing portfolio designed to support new procedures across the continuum of nerve surgery.
Charles Goldfarb (You): And they're not slowing down. With even more innovation on the horizon, we can't wait to see what's next. To learn more about Check Point Surgical and their growing portfolio, visit checkpointsurgical.com.
Charles Goldfarb (You): So, um, a couple of ones— a couple of lesions that I think we see, um, or certainly that are talked about a lot. One is an osteoid osteoma.
Charles Goldfarb (You): Um, you know, these are, um, bony lesions, uh, classically exacerbated by, um, cold exposure, um, and with night pain, relieved, uh, with anti-inflammatories. Uh, can be in the carpus, can be in the phalanx.
Charles Goldfarb (You): I— I— a lot of times I think about distal phalanx, but obviously not only. Um, and it can be pinpoint discomfort.
Charles Goldfarb (You): Uh, again, talked about a lot, not seen by me a lot.
Chris: I don't— I mean, maybe it's seen me, but I have not seen this in practice. Uh, you know, so again, things that are classically taught, commonly tested, good to think about, but something that's come across, uh, in my practice. Again, maybe— maybe I've missed it.
Chris: Hopefully not.
Charles Goldfarb (You): Yeah, and the other is a neural lesion, which I've seen a few times, which are— and the reason I mention it is there's a lot of— a lot of these things we're talking about are benign but can be aggressive or can recur. A neural lesion, you know, the patient comes in, there's a palpable bump, often on a phalanx, and then you get an X-ray and you're like, "Oh my God," you know, "What is this?" And then it's just bony growth that's totally benign, and you take
Charles Goldfarb (You): it off and everyone's happy.
Chris: I'm glad everybody's happy. Again, that— that doesn't come across for me. So I guess as— as we bring things to a close, I think the other thing to consider is I've seen some really funky tophi, like, you know, so sequelae of gout.
Chris: Um, obviously that is something that is much more centered over a joint. Um, and then— but then I've also seen them in the pulp of the thumb or the fingers, and they're just, you know, like some— they're painful to some patients, uh, but those love to come back too.
Chris: Um, so— and that's not a very gratifying feeling when you've excised this megatophus, and it just comes right back and they want it out again. I'm like, "Here we go."
Charles Goldfarb (You): Yeah, for sure. And any type of calcification, whether, you know, it'd be subcutaneous or the like. So, you know, gout, um, uncommon.
Charles Goldfarb (You): Calcifications, uncommon, but they do exist. One of the more common things, uh, that I see, um, on a regular basis is vascular, our vascular lesions.
Charles Goldfarb (You): Um, sometimes, uh, these can be arteriovenous malformations. Uh, sometimes they're just a venous collection.
Charles Goldfarb (You): Uh, how we treat them, I think, varies. You know, recently I saw one that was relatively large in the palm.
Charles Goldfarb (You): I use my interventional radiology colleagues, um, for the bigger ones in the palm where I really want to be successful in excision, I will ask them to inject glue, uh, which may sound crazy for those who haven't done it, but it's a game-changer. Trying to successfully excise these larger lesions, uh, without it can be done, but it's a lot trickier.
Charles Goldfarb (You): Um, the glue just makes it a really enjoyable, straightforward surgery, which still may not be curative, but, uh, for the larger lesions, that's something to keep in your back pocket.
Chris: They inject glue?
Charles Goldfarb (You): Yeah, I bring—
Chris: I've never heard of this. This is— this is crazy. What— so what do they do?
Charles Goldfarb (You): Yeah. No, literally, they— uh, and I don't know the exact parameters of the sterile glue, but as part of the interventional procedure, they inject this substance into the body of the AVM. Um, and, uh, they do that typically the day before a surgery.
Charles Goldfarb (You): Um, and then it— it causes some swelling and it can cause some discomfort. I see these in kids regularly.
Charles Goldfarb (You): Um, and then the next day I go to the OR, and then once you expose the lesion, it's relatively straightforward to take out. Because we've all been in a situation, I presume.
Charles Goldfarb (You): Maybe everyone hasn't, but I sure have, where you go to take out one of these, uh, vascular lesions, typically benign, but if they're larger, and then you put the tourniquet up and you go in there and you're like, "Well, this is, you know, not so impressive," and you try to take it out, especially if it goes deep into the muscle. And it can be an exercise in frustration, uh, that doesn't accomplish what we set out to accomplish.
Charles Goldfarb (You): So this is— this is an option. Of course, just using interventional to treat some of these is an important option as well, but for these in the hand, it's— it's— this has been my preferred approach.
Chris: Cool. I mean, it's— it— it is fascinating to me how you and I practice within 10 miles of each other, and we see such vastly different things. Uh, because I— that just doesn't come across my doorstep, probably because of the age population that you have.
Chris: Um, but that's fascinating. Thank you for teaching me that.
Chris: Uh, maybe as we bring it to a close, I did see one case recently which was cool. It's talked about often in teaching, but it has not come my way, is that, uh, there was a patient who had, um, uh, paresthesias in her ring and small finger and had some mild weakness, um, but didn't really have a Tinel's sign at her elbow.
Chris: Uh, I was thinking this was going to be cubital tunnel. Uh, had some feeling of fullness along her muscles, uh, which was picked up by the fellow.
Chris: And, um, we— we went ahead and got some imaging, and lo and behold, there was a mass adjacent to Guyon's canal. Um, so recently we explored the— we explored that area, just didn't do anything at the elbow.
Chris: Told her she did have some slowing across the elbow on her nerve test, but didn't have a Tinel's and didn't think that was the— in the context of knowing there was a cyst, uh, based on the imaging, just worked in the, uh, in the palm and distal forearm. Uh, and it was a very classic ganglion cyst coming off of, um, uh, the carpus, uh, adjacent to zone one of Guyon's canal, which for me had not come up very often.
Chris: I had a classic exam. It was great.
Chris: Very gratifying. She's— she's excised the mass, decompressed Guyon's canal, and she's very happy.
Charles Goldfarb (You): Yeah, that's— that's a win. I'll share a— a more challenging situation, which is, um, you know, we always should think about infection in these situations, especially in kids. Um, but, you know, they are the atypical mycobacteria we will all see and you will treat, and it's a very challenging process, and getting the right diagnosis and, uh, curing this, or at least controlling this, can be hard.
Charles Goldfarb (You): And I'm— I'm dealing with that situation, uh, currently, and it's just a— a very frustrating time because they can present with relatively localized swelling, um, and you go to try to make a diagnosis, uh, uh, whether it be with imaging or via surgery, and it can be tricky.
Chris: Yeah, I think the old saying is, uh, culture what you biopsy, biopsy what you culture. And anytime your spidey sense or your radar is going off, uh, always send both, just because you never know.
Charles Goldfarb (You): Absolutely. The— the rarities, as we bring this to a close, you know, are vast. Uh, the ones that, you know, we think about, uh, synovial sarcoma, epithelioid sarcoma, um, um, those— those are the ones that I've seen more than others, and by I've seen means once or— once or twice in my career.
Charles Goldfarb (You): It's just not common, but we have to think about those potential diagnoses every time.
Chris: Yeah, and like you said earlier, I mean, pattern recognition, you know, we're clearly not doing it in the same way that our dermatology colleagues do, but you— you know the things that look different and that look, uh, a little off, and that's when you, uh, have a low threshold to either ask for help, like you said, or to, uh, to start some with a biopsy.
Charles Goldfarb (You): Awesome. All right, well, I know that there are many more lesions we did not discuss. Uh, there's skin pathology, etc., but, uh, hopefully this, uh, primer, or maybe they call it a primer in, uh, Scotland, uh, is helpful.
Chris: Oh, you're going to get so much flak for not knowing how to pronounce the— the city that we're going to now.
Charles Goldfarb (You): As we should.
Chris: I'm getting nervous about even trying. So, uh, thanks for everybody for listening. Send us some suggestions. [email protected].
Chris: Look forward to seeing everybody, uh, overseas, across the pond, in Scotland.
Charles Goldfarb (You): Thank you.
You May Also Like

John Michael Godier's Event Horizon
John Michael Godier

Head Shepherd
Mark Ferguson

Vida Eterna. Respuestas desde la Ciencia | Dr. Manuel Sans Segarra
Dr. Manuel Sans Segarra

Outrage + Optimism: The Climate Podcast
Persephonica and Global Optimism

Глобальный доступ на рынок медицинских изделий
Pure Global

Trent Loos Podcast
Trent Loos

The Grave Talks | Haunted, Paranormal & Supernatural
Ghost Stores, Haunted, Paranormal & Supernatural Stories

The Best of Coast to Coast AM
iHeartPodcasts and Coast to Coast AM

Eye On The Sky
Vermont Public

Bedtime Astronomy
Synthetic Universe
Community discussion